/
Cardiovascular
Cardiovascular Disease
59
Pipeline Programs↗
66
Active Trials↗
42
Companies Involved↗
Cardiovascular Disease is a moderately active landscape with 59 programs across 42 companies. The most active players are Novartis, Johnson & Johnson, Bristol-Myers Squibb. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical41
Phase 14
Phase 21
Phase 313
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
46 of 54 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 97% of 59 pipeline programs.
Analysis
Trial Status
192
clinical trials
Completed89 · 46%
Recruiting32 · 17%
Unknown status22 · 11%
Active, not recruiting20 · 10%
Not yet recruiting12 · 6%
Terminated10 · 5%
Other7 · 4%
Clinical Trials
Trial Activity
192 trials
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)